Conference call to discuss the barzolvolimab development program will be held on December 6 at 8 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex presents positive Phase 1b interim data from barzolvolimab in urticaria
- Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
- Celldex to host conference call
- Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
- Celldex to Participate in Upcoming November Investor Conferences